2.3 Autoimmune & Rheumatologic Disease Principles
Key Takeaways
- Antinuclear antibody (ANA) has high sensitivity (>95%) as a screening test for SLE, while anti-dsDNA (titers correlate with lupus nephritis activity) and anti-Smith antibodies provide high specificity (>98%) for confirming diagnosis.
- Rheumatoid Factor (RF) occurs in 70–80% of RA cases but lacks specificity; Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies show equivalent sensitivity with superior specificity (>95%) for RA and predict aggressive erosive disease.
- Synovial fluid analysis differentiates joint effusions: inflammatory arthritis presents with WBC 2,000–50,000/mm³, whereas septic arthritis presents with WBC >50,000/mm³ (often >100,000/mm³) with >75–90% PMNs requiring urgent empiric IV antibiotics and drainage.
- Granulomatosis with Polyangiitis (GPA/Wegener) is strongly associated with PR3-ANCA/c-ANCA (>90% sensitivity in active disease), causing necrotizing granulomas of the upper/lower respiratory tract and pauci-immune glomerulonephritis.
- Anti-Ro/SSA and Anti-La/SSB antibodies cross the placenta in pregnant mothers with Sjögren syndrome or SLE, carrying a risk of neonatal lupus and congenital heart block; Systemic sclerosis subtypes are distinguished by anti-centromere (limited/CREST) versus anti-Scl-70 (diffuse) antibodies.
Autoimmune & Rheumatologic Disease Principles
Diagnostic Approach & Autoantibody Profiling
Autoimmune rheumatologic diseases result from a breakdown of immunological self-tolerance, leading to autoreactive B- and T-cell responses against host tissues. Clinical presentation spans multisystem involvement (Systemic Lupus Erythematosus, Systemic Sclerosis) to targeted organ inflammation (Rheumatoid Arthritis, ANCA-associated vasculitides). On USMLE Step 2 CK, diagnostic evaluation centers on matching specific clinical syndromes with high-yield autoantibody profiles, inflammatory marker patterns, and synovial fluid analysis.
High-Yield Rheumatologic Autoantibody Master Table
| Autoantibody | Target Antigen | Associated Disease State | Sensitivity / Specificity | Clinical Utility & Diagnostic Significance |
|---|---|---|---|---|
| ANA (Antinuclear Antibody) | Nuclear antigens | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjögren | Sensitivity >95% (SLE), Specificity Low (~50%) | Initial screening test for connective tissue disease; negative test strongly excludes SLE |
| Anti-dsDNA | Double-stranded DNA | Systemic Lupus Erythematosus (SLE) | Sensitivity 60–70%, Specificity >98% | Highly specific for SLE; titers correlate with disease activity and lupus nephritis risk |
| Anti-Smith (Anti-Sm) | Core snRNP proteins | Systemic Lupus Erythematosus (SLE) | Sensitivity 20–30%, Specificity >98% | Highly specific diagnostic marker for SLE; titers do NOT fluctuate with disease activity |
| Anti-CCP (Cyclic Citrullinated Peptide) | Citrullinated proteins | Rheumatoid Arthritis (RA) | Sensitivity 70–80%, Specificity >95% | Most specific diagnostic marker for RA; predicts erosive disease progression |
| Rheumatoid Factor (RF) | Fc portion of human IgG | Rheumatoid Arthritis, Sjögren, Hepatitis C | Sensitivity 70–80%, Specificity 70% | Screen for RA; positive in many non-rheumatologic conditions (endocarditis, HCV) |
| c-ANCA (PR3-ANCA) | Proteinase 3 | Granulomatosis with Polyangiitis (GPA / Wegener) | Sensitivity >90% (active disease), Specificity >95% | Associated with upper airway, pulmonary nodular, and pauci-immune glomerulonephritis |
| p-ANCA (MPO-ANCA) | Myeloperoxidase | Microscopic Polyangiitis (MPA), Eosinophilic GPA (EGPA) | Sensitivity 60–80%, Specificity >90% | Associated with pulmonary-renal syndrome without granulomas (MPA) or asthma/eosinophilia (EGPA) |
| Anti-Ro / SSA & Anti-La / SSB | Ribonucleoprotein particles | Sjögren Syndrome, Systemic Lupus Erythematosus | Sensitivity 70–90% (Sjögren), Moderate (SLE) | Associated with sicca symptoms; pregnant mothers risk transmitting neonatal congenital heart block |
| Anti-Centromere | Centromeric proteins | Limited Cutaneous Systemic Sclerosis (CREST) | Sensitivity 60–80%, Specificity >95% | Associated with Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasias |
| Anti-Scl-70 (Anti-Topoisomerase I) | DNA Topoisomerase I | Diffuse Cutaneous Systemic Sclerosis | Sensitivity 30–40%, Specificity >98% | Associated with rapid skin involvement and early progressive interstitial lung disease |
| Anti-Jo-1 (Anti-Histidyl tRNA Synthetase) | tRNA Synthetase | Polymyositis, Dermatomyositis | Sensitivity 20–30%, Specificity >95% | Associated with Antisynthetase syndrome (interstitial lung disease, mechanic's hands, fever) |
| Anti-U1 RNP | U1 small nuclear RNP | Mixed Connective Tissue Disease (MCTD) | Sensitivity >95% for MCTD, Specificity High | Required criterion for diagnosing MCTD (features of SLE, systemic sclerosis, polymyositis) |
Synovial Fluid Analysis & Joint Disease Differentiation
When evaluating a patient with joint pain and effusion, arthrocentesis with synovial fluid analysis is the crucial mandatory diagnostic step to differentiate non-inflammatory, inflammatory, crystal-induced, and septic joint etiologies.
Synovial Fluid Interpretation Matrix
| Fluid Category | Appearance | Clarity | WBC Count (/mm³) | PMNs (%) | Glucose Ratio (Fluid:Blood) | Common Clinical Diagnoses |
|---|---|---|---|---|---|---|
| Normal | Straw/Clear | Transparent | <200 | <25% | ~1.0 | Healthy joint |
| Non-Inflammatory | Yellow | Transparent | 200 to 2,000 | <25% | >0.8 | Osteoarthritis, Trauma, Charcot joint |
| Inflammatory | Yellow to Opalescent | Translucent | 2,000 to 50,000 | 50% to 75% | 0.5 to 0.8 | Rheumatoid arthritis, SLE, Gout, Pseudogout, Reactive arthritis |
| Septic | Turbid / Purulent | Opaque | >50,000 (often >100,000) | >75% to 90% | <0.5 | Staphylococcus aureus, Neisseria gonorrhoeae, Streptococcal infection |
| Hemorrhagic | Red / Bloody | Opaque | 200 to 2,000 (RBCs predominant) | Variable | ~1.0 | ACL tear, Intra-articular fracture, Hemophilia, Anticoagulant overdose |
Diagnostic Evaluation Algorithm for Arthritis
Patient Presenting with Joint Pain & Swelling
├─ Step 1: Physical Exam & History (Monoarticular vs Polyarticular; Inflammatory vs Non-inflammatory)
│ ├─ Inflammatory: Morning stiffness >60 min, improves with activity, systemic symptoms
│ └─ Non-inflammatory: Morning stiffness <30 min, worsens with weight-bearing
│
├─ Step 2: Acute Monoarthritis → MANDATORY ARTHROCENTESIS
│ ├─ Synovial WBC >50,000/mm³ + PMNs >75% → SEPTIC ARTHRITIS (Empiric IV Vancomycin + Cefepime + Surgical Drainage)
│ ├─ Polarized Microscopy: Needle-shaped, negatively birefringent crystals → GOUT (Monosodium urate)
│ └─ Polarized Microscopy: Rhomboid, positively birefringent crystals → PSEUDOGOUT (Calcium pyrophosphate)
│
└─ Step 3: Polyarthritis (Multiple Joints Involved)
├─ Symmetrical Small Joint Involvement (MCPs, PIPs, Wrists; Sparing DIPs)
│ └─ Order RF, Anti-CCP, ESR, CRP, Hand/Wrist Radiographs
│ ├─ Anti-CCP (+) & RF (+) with marginal joint erosions → RHEUMATOID ARTHRITIS
│ └─ Initiate Early Disease-Modifying Antirheumatic Drug (DMARD: Methotrexate)
│
└─ Multisystem Features (Malar rash, Photosensitivity, Serositis, Cytopenias)
└─ Order Initial Screen: ANA (Antinuclear Antibody)
├─ If ANA Positive → Order Specific Panel: Anti-dsDNA, Anti-Smith, Complement C3/C4, Urinalysis
└─ Anti-dsDNA (+), Anti-Sm (+), Low C3/C4 → SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Core Pharmacotherapy & Disease-Modifying Principles
Conventional Synthetic DMARDs
- Methotrexate: First-line disease-modifying therapy for Rheumatoid Arthritis. Acts via competitive inhibition of dihydrofolate reductase, impairing DNA synthesis. Requires co-administration of folic acid (1–5 mg/day) to prevent mucosal ulceration, cytopenias, and hepatotoxicity. Monitoring requires baseline chest radiograph (pulmonary fibrosis risk) and periodic complete blood counts and liver enzymes.
- Hydroxychloroquine: Mild DMARD utilized in SLE and mild RA. Inhibits toll-like receptor signaling. Major adverse effect is retinal toxicity (maculopathy), mandating baseline and annual ophthalmologic examination with visual field testing and optical coherence tomography (OCT).
- Sulfasalazine: Useful in peripheral spondyloarthropathies and RA; metabolized by intestinal bacteria into sulfapyridine and 5-ASA. Side effects include leukopenia and reversible oligospermia.
Biologic DMARDs
- TNF-Alpha Inhibitors (Infliximab, Adalimumab, Etanercept): Potent biologic agents for refractory RA, psoriatic arthritis, and ankylosing spondylitis. Mandatory pre-treatment screening includes Tuberculin skin test (PPD) or Interferon-Gamma Release Assay (IGRA) alongside Hepatitis B virus serologies due to severe risk of reactivation of latent tuberculosis and viral hepatitis.
A 28-year-old female presents to the rheumatology clinic with a 4-month history of joint pain in both hands, facial redness triggered by sun exposure, and profound fatigue. Physical examination reveals an erythematous rash spanning her cheeks and nasal bridge that spares the nasolabial folds, as well as bilateral synovitis of the metacarpophalangeal and proximal interphalangeal joints. Laboratory testing shows a positive serum antinuclear antibody (ANA) with a titer of 1:640 (speckled pattern). Which of the following autoantibodies has the highest specificity for confirming her underlying autoimmune condition?
A 64-year-old male presents to the emergency department with acute onset of severe pain, swelling, and redness in his left knee that began 12 hours ago. He has no history of trauma. Temperature is 38.3°C (101.0°F). Physical examination reveals a large left knee effusion with marked warmth, erythema, and severe restriction of active and passive motion. Arthrocentesis yields 35 mL of opaque, purulent synovial fluid. Synovial fluid analysis reveals a white blood cell count of 88,000/mm³ with 92% neutrophils, absent crystals on compensated polarized light microscopy, and negative Gram stain. Which of the following is the most appropriate next step in management?